問了問gpt:
Roivant Sciences has seen success with several of its subsidiaries and their drug development programs. Some notable successful drugs and programs include:
-
Relugolix:
- Myovant Sciences: Relugolix has been approved for several indications. Under the brand names Orgovyx and Myfembree, relugolix is used for the treatment of advanced prostate cancer and for the management of heavy menstrual bleeding associated with uterine fibroids, respectively. The drug has received FDA approval and has been a significant success for Myovant Sciences.
-
Vibegron:
- Urovant Sciences: Vibegron, marketed under the brand name Gemtesa, is a beta-3 adrenergic agonist approved for the treatment of overactive bladder (OAB). It offers an alternative to existing therapies and has been well-received in the market.
-
Tapinarof:
- Dermavant Sciences: Tapinarof is a topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for the treatment of plaque psoriasis. It has shown promising results in clinical trials and received FDA approval under the brand name Vtama for the treatment of plaque psoriasis in adults.
These successes demonstrate Roivant Sciences' ability to bring promising drug candidates through the clinical development process to market approval and commercial success.
